1	Cerebral perivascular spaces as predictors of dementia risk and accelerated brain
2	atrophy
3	Giuseppe Barisano, M.D., Ph.D. ^{1*} , Michael Iv, M.D. ² , on behalf of the Alzheimer's
4	Disease Neuroimaging Initiative, Jeiran Choupan, Ph.D. ³ , and Melanie Hayden-
5	Gephart, M.D. ¹
6	
7	1. Department of Neurosurgery, Stanford University, Stanford, CA, USA
8	2. Department of Radiology, Stanford University, Stanford, CA, USA
9	3. Laboratory of Neuro Imaging, University of Southern California, Los Angeles, CA, USA
10	
11	*Corresponding author.
12	Department of Neurosurgery, Stanford University,
13	1201 Welch Rd., Stanford, CA, 94305
14	E-mail address: <u>barisano@stanford.edu</u> (Giuseppe Barisano)

16 Abstract

17	Cerebral small vessel disease, an important risk factor for dementia, lacks robust, in
18	vivo measurement methods. Perivascular spaces (PVS) on brain MRI are surrogates for
19	small parenchymal blood vessels and their perivascular compartment, and may relate to
20	brain health. We developed a novel, robust algorithm to automatically assess PVS
21	count and size on MRI, and investigated their relationship with dementia risk and brain
22	atrophy. We analyzed 46,478 clinical measurements of cognitive functioning and 20,845
23	brain MRI scans from 10,004 participants (71.1±9.7 years-old, 56.6% women). Fewer
24	PVS and larger PVS diameter at baseline were associated with higher dementia risk
25	and accelerated brain atrophy. Longitudinal trajectories of PVS markers were
26	significantly different in non-demented individuals who converted to dementia compared
27	with non-converters. In simulated placebo-controlled trials for treatments targeting
28	cognitive decline, screening out participants less likely to develop dementia based on
29	our PVS markers enhanced the power of the trial. These novel radiographic
30	cerebrovascular markers may improve risk-stratification of individuals, potentially
31	reducing cost and increasing throughput of clinical trials to combat dementia.

33 Introduction

Cerebral small vessel disease, the most common vascular disease affecting the blood vessels within the brain parenchyma, is considered a significant and potentially reversible contributor to cognitive decline and dementia.^{1,2} *Ex vivo* studies have shown an independent association of cerebral small vessel neuropathology with cognitive function and many subtypes of dementia.^{3–7} Given the known association with dementia risk, it is important to identify robust radiographic markers of the cerebral small vessels, to properly risk-stratify patients, monitor disease, and assess the impact of treatment.

41 In vivo evaluation of cerebral small vessel disease relies on magnetic resonance imaging (MRI) and includes different signs of brain parenchymal damage (e.g., white matter 42 lesions, lacunes, subcortical infarcts, cerebral microbleeds, and enlargement of 43 44 perivascular spaces).⁸ Yet these MRI findings may not be detectable in the healthy population, lack quantitative granularity, require specific MRI sequences, or are labor 45 intensive to process.^{1,2} Using the perivascular space as detected on MRI to non-46 47 invasively evaluate cerebral small vessel health requires only an unenhanced 3dimensional T1-weighted images,⁹ a nearly universal brain MRI sequence. Current 48 techniques of perivascular space estimation^{10–15} though suffer from user-dependency, 49 and weak or unknown robustness and inter-scanner reproducibility^{1,9,16–18}. These 50 51 limitations prevent generalized, widespread use in the hospital, clinical trials, and multi-52 center longitudinal studies. New, robust tools, therefore, are needed to investigate the temporality and nonspurious dose-response relationship between perivascular spaces 53 (as a surrogate of cerebral small vessels) and dementia. 54

55 To meet this critical need, we developed and validated a novel, fully automated approach to robustly assess the perivascular spaces in the white matter (WM-PVS) and basal 56 57 ganglia (BG-PVS) requiring as input only unenhanced 3-D T1-weighted images. Despite some possible limitations in PVS visual detection compared with T2-weighted images,⁸ 58 59 3-D T1-weighted images are more commonly included in brain MRI protocols.¹⁹ We 60 employed our novel method to investigate the association of baseline PVS with the risk 61 of developing dementia and the brain atrophy trajectory. We focused on two properties: 62 the number of perivascular spaces on T1-weighted image (hereinafter referred to as PVS 63 count), and PVS mean diameter. We also included in our analyses the (log-transformed) 64 volume of white matter lesions in the periventricular area (P-WML) and deep white matter (D-WML), since they can similarly be measured on T1-weighted images and are 65 considered closely related to PVS.⁸ 66

Given that the inclusion of individuals with low risk of cognitive decline reduces the power of clinical trials evaluating a treatment effect on cognitive impairment,²⁰ we evaluated the potential benefit of our novel PVS markers as a screening tool to enrich for individuals likely to develop dementia and compared their performance with that of standard WML and atrophy markers assessed on T1-weighted images.

72 **Results**

73 Technical validation of PVS and WML markers

The spatial overlap between the PVS masks obtained with our novel fully automated approach and those obtained with a previously validated semi-automated technique^{12,13,17}

76 was very high (average Dice similarity coefficient: 0.95 ± 0.0001) and the numbers of PVS voxels identified with the two methods were strongly correlated (Spearman's ρ =0.94, 77 P<0.001, Fig. S3A). Consistently, PVS measured with our method also showed a strong 78 79 positive association with age, male sex, and body mass index in the Human Connectome 80 Project dataset (Fig. S3B-D), replicating results previously published with the validated semi-automated techniques.^{21–23} These data support the reliability and accuracy of our 81 82 PVS masks. While previous methods are user-dependent (i.e., the user needs to identify 83 a threshold for each type of T1-weighted image) and lack inter-scanner reproducibility of PVS markers^{1,9,16–18} (Fig. S1A-B), our technique is able to provide measurements of PVS 84 85 count and diameter in a fully automated and robust way. Indeed, both metrics showed 86 excellent intraclass correlation coefficients (≥0.9 for WM-PVS and ≥0.8 for BG-PVS) for 87 inter-scanner reproducibility, inter-field-strength reproducibility, and test-retest 88 repeatability (Figure S4). We also observed a strong correlation between the numbers of 89 PVS voxels independently identified by our algorithm on the T1- and T2-weighted images 90 (Spearman's ρ =0.98, P<0.001, Fig. S5A), with an average of 87.3±5.7% of PVS voxels 91 detected on T1-weighted images that overlapped with PVS voxels on T2-weighted 92 images. Overall, these data show that our method can accurately segment PVS on T1-93 weighted images and that T1-weighted images are suitable to reliably assess PVS morphological metrics and inter-subject differences. In contrast with previous methods,¹⁰⁻ 94 95 ¹⁵ our new approach for PVS segmentation is fully automated, requires only T1-weighted images, and provides robust metrics across different scanners and protocols (Figure S4). 96 97 Concerning the segmentation of WML, which we performed with a previously validated 98 technique,²⁴ we confirmed that T1-weighted images, despite considered less sensitive

than FLAIR images for the detection of WML,⁸ allow to obtain valid estimates of WML 99 100 volume, as the number of WML voxels detected on T1-weighted images were strongly 101 correlated with those detected on FLAIR (Spearman's ρ =0.82, P<0.001, Fig. S5B), and 102 83.0±0.4% of WML voxels detected on T1-weighted images spatially overlapped with 103 WML voxels detected on FLAIR. The derived measurements of WML volume also 104 showed excellent intraclass correlation coefficients (≥ 0.95 for P-WML, ≥ 0.83 for D-WML) 105 for inter-scanner reproducibility, inter-field-strength reproducibility, and test-retest 106 repeatability (Figure S6).

107 Study population

108 The baseline characteristics of the 10,004 participants stratified by study cohort are 109 reported in Table 1. There were 8867 non-demented subjects and 1137 patients with 110 dementia, including 996 clinically diagnosed with probable or possible Alzheimer's 111 dementia, 51 Lewy body dementia, 38 frontotemporal dementia, 1 vascular dementia, 112 and 51 other or uncertain type of dementia. Accuracy of the PVS masks were visually 113 verified for all the cases in a blinded fashion by an expert physician-scientist according to 114 established criteria.⁸ We also developed an interactive website that allows the readers to 115 visualize our PVS segmentations and independently verify their accuracy: 116 https://gbarisano.shinyapps.io/pvs-dementia.

In multivariate analyses, all PVS and WML markers were significantly associated with
age, sex, body mass index, cognitive scores, and history of hypertension (Table S2).
History of diabetes was associated with all PVS markers except BG-PVS diameter;
history of cardiovascular disease was associated with BG-PVS diameter. In the subgroup

analysis (Table S3), WM-PVS count was not significantly associated with APOE
genotype, amyloid or tau status, and BG-PVS count was negatively associated with
amyloid status and APOE-ε4ε4-carrier status. WM-PVS diameter, P-WML and D-WML
volume were associated with positive amyloid and APOE-ε4ε4-carrier status. BG-PVS
diameter was associated with positive tau and APOE-ε4ε4-carrier status.

After controlling for study cohort, demographic, and clinical variables, demented patients showed significantly lower WM- and BG-PVS count, higher WM- and BG-PVS diameter, and higher P-WML volume compared with non-demented subjects (estimated marginal means in Table S4). Consistent results for WM-PVS count, BG-PVS count, and P-WML were obtained in sensitivity analyses (Table S5), indicating that their differences are independent of APOE, amyloid, or tau status.

132 PVS markers and risk of dementia

133 Among 7518 non-demented participants with at least 1 follow-up visit (Table S6), 1493 134 individuals developed dementia during a median follow-up of 4.1 years (interguartile 135 range, 2.3-7.1), including 1306 clinically diagnosed with probable or possible Alzheimer's 136 dementia, 43 Lewy body dementia, 29 frontotemporal dementia, 16 vascular dementia, 137 and 99 other or uncertain type of dementia. In the fully adjusted models of the two-stage 138 pooled analysis, risk of dementia was significantly associated with baseline WM-PVS and 139 BG-PVS count and diameter. Each additional 100 WM-PVS and 10 BG-PVS were 140 significantly associated with 20% and 9% decreased dementia risk, respectively, and 141 each additional 0.1-mm increase in WM-PVS and BG-PVS mean diameter were 142 significantly associated with 9% and 20% increased dementia risk, respectively (Fig. 1A-

143 D). P-WML, but not D-WML, was also significantly associated with dementia risk (Fig. 1E-144 F). The spline analysis with pooled data supported a linear association over the range of 145 the PVS and P-WML markers measured in this population (Fig. 1G-K). Sensitivity 146 analyses showed substantially unchanged results, suggesting that these effects are 147 independent of other potential confounding factors, including the positivity status for 148 amyloid or tau biomarkers (Table S7 and Fig. S7). The association of WM-PVS diameter 149 with dementia risk became not statistically significant after adding amyloid status in the 150 model.

151 PVS markers and brain atrophy

152 Among 3389 non-demented participants with at least 2 MRI scans (Table S8), we 153 investigated the association of PVS and WML markers measured at the baseline MRI 154 with the trajectory of brain atrophy estimated over a total of 14,229 MRI scans (average 155 of 4 scans available per subject) during a median follow-up time of 3.1 years (interquartile 156 range 2.0 to 5.6 years). In the mixed-effect models fully adjusted for demographic, clinical, 157 and MRI-related covariates, the association of PVS and WML markers with the 158 longitudinal trajectory of brain atrophy were statistically significant (Fig. 2A, Table S9). 159 Each additional 100 WM-PVS and 10 BG-PVS identified at the baseline were associated 160 with preservation of additional 709±100 mm³ and 187±33 mm³ of total grey matter volume 161 every year, respectively. Each 0.1 mm increase in WM-PVS and BG-PVS diameter was 162 associated with loss of additional 382±84 mm³ and 576±137 mm³ of total grey matter 163 volume every year, respectively. Each logarithmic unit increase in P-WML and D-WML volume was associated with loss of additional 288±46 mm³ and 189±62 mm³ of total grey 164 165 matter volume every year, respectively. Similar results were obtained for cortical

166 thickness (Fig. 2B, Tables S9). Most of the effects for the grey matter volume and cortical 167 thickness were observed in the temporal lobes, bilaterally, for all markers (Fig. 2A-B 168 bottom rows, respectively; Tables S10 and S11, respectively). For white matter volume, 169 only WM-PVS count, BG-PVS count and BG-PVS diameter were significantly associated 170 with accelerated atrophy (Fig. 2C, Tables S9). These effects and their spatial patterns 171 remained significant for most markers in all sensitivity analyses, indicating that the link 172 between these markers and accelerated atrophy is independent of other potential 173 confounding factors, including the positivity status for amyloid or tau biomarkers (Figures 174 S8-S10, Table S13). Exceptions included WM-PVS and BG-PVS diameter, which 175 became not significant after adding tau status in the model for grey matter volume (Fig. 176 S8, Table S13), but remained significant for cortical thickness (Fig. S9, Table S13); BG-177 PVS diameter became not significant after adding amyloid status in the model for white 178 matter volume (Fig. S10, Table S13). Overall, these data showed that fewer WM-PVS 179 and BG-PVS counts were associated with accelerated brain atrophy. This effect was 180 stronger on the grey matter volume and cortical thickness of the temporal lobes, 181 irrespective of amyloid and tau positivity status. Similar associations were found for WM-182 PVS and BG-PVS diameter, although they were generally less robust when considering 183 amyloid and/or tau status in the model.

We further assessed the relationship between the WM-PVS marker measured in a specific lobe and the corresponding atrophy in that lobe. The spatial patterns for regional WM-PVS count (Fig. S11, left column) were consistent with those observed in the main model with global WM-PVS count (Fig. 2). Less consistency was observed for regional WM-PVS diameter (Fig. S11, right column). This suggests a spatial relationship between

the atrophy trajectory of a specific brain region and the corresponding WM-PVS count inthat region at baseline.

191 Based on previous results from preclinical studies^{25,26}, we hypothesized that one potential 192 mechanism linking PVS with accelerated brain atrophy could be alterations in cerebral 193 blood flow. Indeed, in most of the brain regions we observed a significant correlation of 194 the regional PVS count and diameter with the corresponding regional cerebral blood flow 195 as assessed in vivo with arterial spin labeling MRI (Fig. S12). This suggested that the 196 observed effects of PVS on accelerated brain atrophy might have been related to 197 decreased blood flow. However, the relatively low sample size of subjects with cerebral 198 blood flow data available at the baseline (N=224) prevented us from building reliable 199 linear mixed-effects models evaluating the relative contribution of cerebral blood flow and 200 PVS to the brain atrophy trajectory while accounting for the relevant clinical and 201 demographic covariates included in all our models. No significant correlations with 202 cerebral blood flow were found for P-WML and D-WML (Fig. S12).

203 Finally, we estimated the longitudinal trajectory of the PVS and WML markers in non-204 demented individuals who converted to dementia and compared it with those who did not 205 convert. The WM and BG regions where PVS were measured were spatially-registered 206 and kept consistent across the intra-individual timepoints. This means that, for each 207 subject, PVS were analyzed in the exact same voxels across timepoints. The longitudinal 208 trajectories of PVS count and mean diameter significantly differed between converters 209 and non-converters, both in the white matter and in the basal ganglia: PVS count in 210 converters, who already had lower PVS count compared with non-converters at the 211 baseline MRI (Table S14), further decreased with time. PVS count remained stable in

212 non-converters (Figure 3A and C). On the other hand, WM-PVS and BG-PVS mean 213 diameter (Figure 3B and D, respectively) were stable in converters, who already had 214 significantly higher baseline PVS diameter compared with non-converters (Table S14). 215 WM-PVS and BG-PVS mean diameter decreased in non-converters. Sensitivity analyses 216 showed consistent results (Figure S13), indicating that the different trajectories for these 217 markers in converters versus non-converters were independent of other potential 218 confounding factors such as amyloid and tau status. In WM-PVS markers, the differences 219 between converters and non-converters involved mostly the left hemisphere, especially 220 the frontal and parietal lobes (Figure 3A and B). Significant increases over time in P-WML 221 volume were also found, which were more prominent in converters compared with nonconverters (Figure 3E). Overall, these data indicate that the differences in PVS count and 222 223 diameter measured at the baseline MRI scans of dementia converters versus non-224 converters followed different longitudinal trajectories: in converters, larger baseline PVS 225 remain enlarged, and lower baseline PVS count continue decreasing.

226

227 PVS markers in simulated clinical trials

In 48-month placebo-controlled trials simulated with 40,703 cognitive assessments in 7518 non-demented participants, the sample size required to detect a 30% slowing in cognitive decline (assessed with the CDR) with 80% power was lower when selectively screening out participants based on the PVS or the WML markers' tertiles (Table S16): sample size reductions were 13-37% when enrolling participants in the medium- and highrisk tertiles (Figure 4, red bars), and 28-63% when enrolling participants in the high-risk tertile only (Figure 4, blue bars). The performance was comparable to that observed for
the atrophy markers cortical thickness and grey matter volume (respectively 53% and
37% reductions when including individuals in the high-risk tertile). Similar results were
obtained with simulations where the cognitive decline was assessed with the MMSE (Fig.
\$14).

After controlling for demographic covariates, medium- and high-risk tertiles for PVS markers were not significantly associated with amyloid or tau positive status (Table S15), suggesting that screening non-demented participants according to our PVS markers is not linked to Alzheimer disease biomarkers. On the other hand, medium- and high-risk tertiles for P-WML volume, cortical thickness, and grey matter volume were associated with amyloid positive status (Table S15).

245

246 Discussion

247 We developed a novel, fully automated, and robust algorithm to obtain unbiased, quantitative metrics of PVS from clinical brain MRI T1-weighted images. We 248 249 demonstrated that our method provides accurate segmentations with high inter-scanner 250 and inter-field-strength reproducibility. These characteristics allowed us to apply this 251 algorithm to the brain MRI scans of 10,004 subjects whose data were pooled from three 252 publicly available studies performed in the United States and Canada. We found that after 253 controlling for demographic and clinical covariates, lower PVS count and higher mean 254 PVS diameter were significantly associated with a dose-response higher risk of 255 developing dementia, and with accelerated brain atrophy. The robustness and reliability

of these results is related to the large sample size, the use of individual-level data and consistent approaches for covariate adjustments and modeling, and the consistency across multiple sensitivity analyses. These data show that PVS may represent a predictor of dementia.

260 Perivascular spaces represent a critical component of the glymphatic system, a system thought to be responsible for brain clearance of toxic and waste metabolites.²⁷ A 261 262 larger perivascular diameter might indicate alterations in the glymphatic flow and 263 impairment of the clearance process, with subsequent accumulation of neurotoxic protein aggregates in the brain.^{25,28,29} In agreement with preclinical studies showing a relationship 264 between glymphatic system and blood flow^{25,26}, we found that PVS diameter was 265 266 inversely correlated with cerebral blood flow. On the other hand, PVS count was positively 267 correlated with brain perfusion, with a higher PVS count also associated with lower risk 268 of dementia and slower brain atrophy. Since the PVS count obtained with our method 269 included any MRI-visible PVS, regardless of whether they could be considered enlarged 270 or not, PVS count may be linked to brain perfusion rather than to glymphatic dysfunction. A low PVS count might indicate cerebral hypoperfusion, a factor found associated with 271 cognitive decline and brain atrophy.^{30–33} 272

Studies prior to ours performed manual visual assessment of perivascular spaces, a significant impediment for large studies and clinical trials, with serious concerns regarding inter- and intra-rater variability. This has led to mixed conclusions on the relationship between PVS and dementia. For example, previous meta-analyses investigated the relationship between WM-PVS and risk of dementia, but the results were conflicting, with significant heterogeneity between studies, variability in methods, and

inconsistent adjustment for confounding factors.^{1,34,35} Other studies in smaller cohorts 279 280 also reported diverging results: some showed an association between perivascular space enlargement and higher risk of dementia,^{36,37} while others found no increased risk³⁸ or 281 282 increased risk of vascular dementia only.³⁹ Importantly, in all these studies the manual 283 visual assessment prevented a quantitative analysis of the blood vessels with small/non-284 enlarged perivascular spaces, a limitation eliminated by our novel algorithm. Moreover, 285 visual readings typically do not consider in their assessment the total intracranial volume, a factor strongly associated with PVS⁹ and that we controlled for in all our models. 286

287 Our novel MRI PVS markers required only a commonly acquired volumetric T1-288 weighted sequence, were computed in a fully-automated fashion, and showed excellent 289 inter-scanner and test-retest reproducibility. These features may allow for our PVS 290 markers to be readily implemented in clinical practice, as well as retrospective analyses 291 of currently available brain MRI data. As we showed in our clinical trial simulations, their 292 use may reduce the cost and duration of clinical trials for dementia prevention and 293 treatment by facilitating the identification and enrollment of individuals with increased risk of cognitive decline. Indeed, we found that after screening out participants based on our 294 295 PVS markers, there was a substantial reduction in the minimal number of individuals 296 required for detecting the intervention effect, suggesting an increase in the power of the 297 trial. Importantly, medium and high-risk tertiles of our PVS markers were not linked to 298 positive amyloid and tau status, in contrast with WML and atrophy markers, indicating 299 that the selection of individuals based on our PVS markers is independent of Alzheimer 300 disease biomarker status. In the case of trials for treatments specifically targeting 301 Alzheimer disease hallmark pathology such as amyloid- β and tau (i.e., enrolling

302 individuals positive for amyloid- β and/or tau), these PVS markers would allow to identify 303 and exclude individuals at high risk of vascular/perivascular co-pathology, enhancing the 304 trial for a more homogenous cohort of preclinical Alzheimer disease. Early detection of 305 an increased risk of dementia could also motivate individuals to adopt healthy lifestyle 306 modifications, encouraging healthcare professionals to implement preventive measures 307 and initiate timely treatments and support, thereby improving patient and family member 308 guality of life. Finally, these novel MRI markers open new opportunities to robustly 309 investigate perivascular spaces in vivo in a variety of other neurological conditions and 310 treatment paradigms, allowing to gain new insights on the human brain vasculature and glymphatics. 311

We acknowledge the following limitations in our study. First, our analytic approach 312 313 allowed us to reduce the degree of heterogeneity across studies, but some heterogeneity 314 remained, intrinsic to the original study design, such as the health profile of participants 315 and availability and type of information on covariates. Second, we could not assess the 316 potential role of residual confounding factors, such as diet and socioeconomic status, which were not available in the analyzed databases. Third, as we were restricted to 317 318 populations recruited by the original studies, our cohort comprised mainly white 319 participants, and increased representation of other racial and ethnic groups would be 320 critical to generalization. Fourth, we cannot exclude that small lesions with vascular shape 321 may be included in our PVS segmentation masks. Nevertheless, the influence of these 322 potential lesions to our statistical analyses may be considered negligible, since even a 323 few lesions in a single subject would represent a very small proportion of the total PVS 324 count estimated in that subject (interquartile range of WM-PVS and BG-PVS per subject

in our study were 339-530 and 106-166, respectively). Finally, we could not discriminate whether our PVS metrics refer to periarteriolar or perivenous compartment. However, previous studies have shown that the majority of the MRI-visible PVS overlap with arterioles,^{40–42} therefore it is reasonable to assume that the PVS metrics in our analysis refer mostly to arterioles and their periarteriolar compartment.

In conclusion, using our novel, fully-automated, robust algorithm for assessing perivascular spaces in the cerebral white matter and basal ganglia, we found a significant linear association of low PVS count and high PVS diameter with increased risk of dementia and accelerated brain atrophy. These results support a link between PVS and cognitive impairment, opening new opportunities to risk-stratify individuals for clinical trial enrollment, early healthcare interventions to combat dementia, and accelerated research in human brain glymphatics.

337 Online Methods

338 Study Population

339 We combined data from three observational community-based studies: the Alzheimer's Disease Neuroimaging Initiative (ADNI)⁴³ (MRI data downloaded on March 2023), the 340 National Alzheimer's Coordinating Center (NACC) database⁴⁴ (December 2022 data 341 freeze), and the Open Access Series of Imaging Studies (OASIS-3)⁴⁵ (Data release 2.0, 342 343 July 2022). Enrolled subjects include both cognitively unimpaired individuals and patients 344 with cognitive impairment and dementia. All participants undergo standardized clinical 345 and neuropsychological examination. All the studies obtained institutional review board approval and written informed consent from all participants. 346

347 We included in our analysis all participants who underwent 1) at least one clinical visit 348 with cognitive assessment data available and 2) a brain MRI scan including an 349 unenhanced 3-dimensional T1-weighted sequence within 12 months from the baseline 350 clinical visit. In the analysis investigating the risk of dementia, and in the simulated clinical 351 trials, only baseline non-demented subjects with at least 1 follow-up clinical visit were included (definition of dementia is described in the following section). In the analysis of 352 353 PVS and brain atrophy trajectories assessed with MRI, only baseline non-demented subjects with at least 1 follow-up MRI scan were included. 354

355 Specific details on the individual study designs and enrollment criteria are provided below.

356

358 ADNI

359 ADNI is a longitudinal multicenter study conducted in the United States and Canada to 360 develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and 361 tracking of Alzheimer's disease (AD). ADNI began in 2004 and enroll cognitively 362 unimpaired or impaired subjects between 55 and 90 years of age (inclusive) with a study partner to provide an independent evaluation of functioning.⁴⁶ All subjects could not have 363 364 any medical contraindications to Magnetic Resonance Imaging (MRI), could not be 365 enrolled in other trials or studies concurrently, and could not take any medication that could affect cognitive function.⁴⁶ All subjects had to have Hachinski Ischemic Score of 366 less than or equal to 4;47 permitted medications stable for 4 weeks prior to screening; a 367 Geriatric Depression Scale score of less than 6⁴⁸ a study partner with 10 or more hours 368 369 per week of contact either in person or on the telephone and who could accompany the 370 participant to the clinical visits; visual and auditory acuity adequate for neuropsychological 371 testing; good general health with no diseases precluding enrollment; 6 grades of 372 education or work history equivalent; and ability to speak English or Spanish fluently. 373 Women had to be sterile or 2 years past childbearing potential.

At the screening visit, all subjects were required to provide informed consent as compatible with the local sites (Institutional Review Board regulations). In addition, all subjects provided demographics, family history, and medical history. All subjects were given a physical examination and a neurologic examination, and vital signs were recorded. The haplotype of apolipoprotein E (APOE) gene was assessed on blood samples. Cerebrospinal fluid samples were collected in a subsample of the participants: Amyloid- β_{1-42} , total Tau, and phosphorylated Tau₁₈₁ measurements were completed using

the Roche Elecsys Cobas E601 fully automated immunoassay platform at the ADNI
biomarker core (University of Pennsylvania) and were available for 61.3%, 61.2%, and
61.2% of the participants included in our analysis.

Data on amyloid tracers uptake on Positron Emission Tomography (PET), including florbetapir (AV-45), florbetaben (FBB), and Pittsburgh compound B (PiB), were available in 66.7% of participants. Quantitative measurements of standardized uptake value ratio (SUVR) were provided by the ADNI PET core (University of California, Berkeley) following protocols described in the ADNI website (<u>https://adni.loni.usc.edu/methods/pet-analysis-</u> <u>method/</u>).

Participants were classified as amyloid-positive based on abnormal amyloid level detected on cerebrospinal fluid (<1098 pg/ml)⁴⁹ or PET (thresholds recommended in the ADNI PET core documentation: AV-45>1.11,⁵⁰ FBB>1.08,⁵¹ PiB>1.5⁵²), and as taupositive based on abnormal level of total tau (>242 pg/ml) or phosphorylated tau (>19.2) on cerebrospinal fluid.⁴⁹

395 Quantitative measurements of cerebral blood flow in units of ml/100mg/min from Arterial Spin Labeling MRI were available in a subsample of 1154 scans acquired on 450 396 397 subjects, and were performed by the University of California, San Francisco, following 398 protocols described in the ADNI website. The Arterial Spin Labeling techniques included 399 223 3D pseudo-continuous arterial spin labeling (pCASL) and 931 pulsed arterial spin 400 labeling (PASL, 918 2D and 13 3D). We used these measurements in an exploratory 401 analysis to assess the correlation between cerebral blood flow and the corresponding 402 WM-PVS count estimated with our novel algorithm, while controlling for age, sex, race, 403 educational level, body mass index, history of diabetes, cardio-/cerebro-vascular disease,

404 hypertension, dyslipidemia, family history of dementia, the employed arterial spin labeling
405 technique, the total intracranial volume and the volume of the region where cerebral blood
406 flow was assessed.

407

408 NACC

409 The NACC database comprises data collected from the Alzheimer's Disease Centers in 410 the United States funded by the National Institute on Aging. From 2005 to the present, 411 these centers have been contributing data to the Uniform Data Set using a prospective, 412 standardized, and longitudinal clinical evaluation of the enrolled subjects, including both cognitively unimpaired individuals and patients with cognitive impairment and dementia. 413 414 Participants are enrolled on a referral or volunteer basis and undergo a complete 415 examination yielding demographic data, neuropsychological testing scores, and clinical 416 diagnosis. The haplotype of APOE is run independently by each Alzheimer's Disease 417 Center and reported in the NACC database. Cerebrospinal fluid samples were collected 418 in a subsample of the participants: Amyloid- β_{1-42} , total Tau, and phosphorylated Tau₁₈₁ measurements were available in 363 (including 206 obtained through enzyme-linked 419 420 immunosorbent assay, ELISA, and 157 through Luminex), 355 (including 193 ELISA and 421 162 Luminex), and 349 (including 192 ELISA and 157 Luminex) participants. A clinical 422 report of abnormal level of amyloid and tau in cerebrospinal fluid was also available in 96 423 and 91 participants, respectively. Amyloid PET scans were available in 206 participants 424 (111 AV-45 and 95 FBB) and were visually assessed for amyloid positivity by an 425 experienced physician-scientist. A clinical report of abnormal uptake of amyloid and tau 426 tracers in PET were also available in 432 and 26 participants, respectively. Participants

427 were classified as amyloid-positive based on abnormal amyloid level detected on 428 cerebrospinal fluid (<570 pg/ml for ELISA⁵³ or <192 pg/ml for Luminex⁵⁴) or on PET 429 (visually) or as indicated in the clinical report, and as tau-positive based on abnormal level 430 of total tau (>412 pg/ml for ELISA⁵³ and >93 pg/ml for Luminex⁵⁴) or phosphorylated tau 431 (>78 pg/ml for ELISA⁵³ and >23 pg/ml for Luminex⁵⁴) on cerebrospinal fluid or as indicated 432 in the clinical report.

433

434 OASIS

435 OASIS-3 is a retrospective compilation of data collected over the course of 15 years as part of research studies at Washington University in St. Louis.⁴⁵ Participants were 436 recruited from the community via flyers, word of mouth, and community engagements.⁴⁵ 437 438 Enrolled participants included individuals considered generally healthy or without medical conditions that precluded longitudinal participation or contraindications to study 439 procedures, such as MRI and lumbar puncture.45 Participants underwent clinical 440 441 assessments which comprised collection of medical and family history, physical examination, and neuropsychological evaluation.⁴⁵ No cerebrospinal fluid data were 442 443 available for the participants included in our analysis. Data on amyloid and tau tracers uptake on PET were available in 73.3% and 31.2% of participants, respectively. Amyloid 444 445 tracers included AV-45 in 336 cases and PiB in 656 cases, whereas the employed tau 446 tracer was Flortaucipir (18F-AV-1451). Quantitative measurements of the tracer uptake were provided in OASIS-3. The acquisition and processing protocols are fully described 447 448 in the OASIS-3 documentation (https://www.oasis-brains.org/files/OASIS-449 <u>3 Imaging Data Dictionary v2.3.pdf</u>). We used the cutoff values recommended in the

450 OASIS-3 documentation to classify participants as amyloid-positive (Centiloid AV451 45>20.6 or Centiloid PiB>16.4) and as tau-positive (AV-1451 Tauopathy>1.22).
452

453 Assessment of cognitive status and dementia

In all three cohorts, the Clinical Dementia Rating (CDR) assessment⁵⁵ was performed 454 455 through standardized interview with the participant and a knowledgeable informant. Six 456 categories of cognitive functioning (memory, orientation, judgment and problem solving, 457 community affairs, home and hobbies, and personal care) were assessed. We used the 458 standard CDR global score cutoff value of 1 to classify participants as demented (1 and above) or non-demented. The Mini-Mental Status Examination⁵⁶ (MMSE) scores were 459 460 available in a subgroup of 7046 participants and were used only in sensitivity analyses. 461 MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy 2 overlapping pentagons.⁵⁶ 462 463 We did not categorize participants based on the clinical diagnosis when available due to 464 the lack of scientific consensus and the variability in the diagnostic criteria adopted within 465 and across the studies.

466

467 MRI data processing

MRI data were acquired with a variety of 1.5- and 3-Tesla MRI scanners and sequences (Table S1). All T1-weighted images were processed using the *recon-all* module of the freely available FreeSurfer software package (v7.4),⁵⁷ which resampled all the images to 1 mm isotropic resolution and performed an atlas-based brain parcellation. The Iongitudinal processing scheme was used for estimating brain atrophy (grey and white matter volumes, and cortical thickness) longitudinally.⁵⁸ White matter lesions (WML) were segmented with a previously validated approach on T1-weighted images.²⁴ We classified as periventricular WML the clusters of WML adjacent to the lateral ventricles; the remaining clusters of WML were classified as deep WML.

477

478 Robust PVS segmentation method development and validation

The filter developed by Frangi et al.¹⁶ enhances tubular, vessel-like structures on a gray-scale image and assigns a "vesselness" value to each voxel $\mathcal{V}(s)$ from eigenvectors λ of the Hessian matrix \mathcal{H} of the image as:

482
$$\mathcal{V}(s) = \begin{cases} 0 & \text{if } \lambda_2 > 0 \text{ or } \lambda_3 > 0, \\ \left(1 - \exp\left(-\frac{\mathcal{R}_A^2}{2\alpha^2}\right)\right) \exp\left(-\frac{\mathcal{R}_B^2}{2\beta^2}\right) \left(1 - \exp\left(-\frac{\mathcal{S}^2}{2c^2}\right)\right) \end{cases}$$

483 Where,
$$\mathcal{R}_A = \frac{|\lambda_1|}{|\lambda_2|}$$
, $\mathcal{R}_B = \frac{|\lambda_1|}{\sqrt{|\lambda_2\lambda_3|}}$, $S = ||\mathcal{H}||$.

484 We and others previously implemented and validated this filter for the segmentation of 485 MRI-visible vascular and perivascular spaces on T1-weighted images using the default, recommended parameters of α =0.5, β =0.5, and c set to half the value of the maximum 486 Hessian norm.^{12,13,59} This approach requires the user to identify a threshold on the 487 488 vessel map generated by the filter to define the vessel-like structures: values above that 489 threshold (i.e., with high "vesselness" values) are considered vascular and perivascular 490 spaces, and values below are excluded. However, since the scale of the "vesselness" 491 values generated by the filter differs from image to image (Figure S1 A) depending on the signal intensity values of the input image,¹⁶ and since the signal intensity values on 492

493	T1-we	ighted images are represented in arbitrary units which may vary depending on the								
494	MRI m	nachine and its calibration, this approach lacks inter-scanner reproducibility ^{1,9,16–18}								
495	(Fig. S1 B) and is potentially biased even in longitudinal studies. To overcome this									
496	issue, we developed and validated a novel approach for the segmentation of MRI-visible									
497	vessel-like structures applicable to virtually any type of T1-weighted image.									
498	The M	RI data used for the method development and validation were acquired as part of								
499	the Bi	omarkers Consortium for Vascular Contributions to Cognitive Impairment and								
500	Deme	ntia (MarkVCID), ⁶⁰ the Alzheimer Disease Neuroimaging Initiative (ADNI), ⁴³ and								
501	the Hu	Iman Connectome Project (HCP development, ⁶¹ young adults, ⁶² and aging ⁶³), and								
502	includ	ed:								
503	a)	the inter-scanner reproducibility dataset: 19 participants who underwent four								
504		brain MRI scans within an interval of 3 to 90 days on four different 3-Tesla MRI								
505		scanners (General Electric system 750W, Philips Achieva dStream, Siemens								
506		Prisma, and Siemens TIM Trio) from MarkVCID;								
507	b)	the inter-field-strength reproducibility dataset: 299 MRI sessions from 115 ADNI								
508		participants who underwent in each session two brain MRI scans on the same								
509		day with a 1.5- and a 3-Tesla scanner;								
510	c)	the test-retest dataset: 39 participants from MarkVCID who underwent two brain								
511		MRI scans on the same MRI scanner using the same protocol within an interval								
512		of 1 to 14 days;								
513	d)	the biological validation dataset: 2163 healthy individuals from the HCP whose								
514		MRI-visible vascular and perivascular spaces have been studied extensively ^{21–23} ,								
515		providing a reference for verifying established associations.								

516	Tables S17 and S18 include the details for the baseline characteristics of the analyzed
517	individuals and the MRI protocols employed in each of the above datasets, respectively.
518	Our novel approach is based on the observation that the total number of voxels with
519	non-zero vesselness value obtained from the Frangi filter applied on T1-weighted
520	images is:
521	1) consistent across brain images of the same participant acquired with different
522	MRI scanners (inter-scanner and inter-field-strength reproducibility, Figure S2 A
523	and B);
524	2) consistent across brain images of the same participant acquired on two different
525	MRI sessions with the same MRI scanner and protocol (test-retest repeatability,
526	Figure S2 C);
527	3) Significantly associated with age, sex, and body mass index (Figure S2 D-F) as
528	previously described for PVS. ^{21–23}
529	
530	Therefore, we hypothesized that the value of the voxel corresponding to a single,
531	specific percentile of the total number of voxels with non-zero "vesselness" values could
532	be used as a threshold for consistently and robustly segmenting MRI-visible vessel-like
533	structures across different types of T1-weighted images (Figure S1 C-D). We identified
534	this percentile to be 85%, based on the average ratio between the number of voxels that
535	we previously segmented as vascular and perivascular spaces in the HCP dataset 21,22
536	and the corresponding total number of voxels with non-zero vesselness value.
537	In each individual vesselness map generated by the Frangi filter, the vesselness value
538	corresponding to the 85 th percentile of the total number of non-zero voxels was

539 automatically computed: the voxels with vesselness value above this threshold were 540 retained and binarized to make the PVS mask, whereas those below or equal to the threshold were excluded. To improve the specificity of the PVS segmentation.^{17,59} the 541 542 Frangi filter was applied on FreeSurfer's white matter mask with the following 543 modifications: the voxels labeled as corpus callosum by FreeSurfer were excluded: 544 periventricular areas were excluded by subtracting FreeSurfer's lateral ventricle binary 545 mask enlarged by 3 units from the white matter binary mask; white matter lesions (WML) segmented with SAMSEG²⁴ were also excluded. Finally, we used MATLAB's 546 547 regionprops3 function with the default 26-connected neighborhood definition to compute PVS count and mean diameter across all PVS clusters with in-plane size of at least 2 548 549 voxels detected in the modified white matter mask of each subject. 550 Accuracy of the PVS segmentation was assessed via visual inspection and guantified 551 with the Dice similarity coefficient using as a reference the PVS masks obtained with an 552 established and previously validated technique applied on the HCP dataset (Fig. S3A).^{12,13,17,23} The Dice similarity coefficient ranges from 0, indicating no spatial overlap 553 554 between two sets of binary segmentation masks, to 1, indicating complete overlap. 555 The robustness of the PVS metrics assessed in our study (i.e., PVS count and PVS mean 556 diameter) across different MRI scanners (inter-scanner and inter-field-strength

reproducibility) and sessions (test-retest repeatability) was assessed with the intraclass correlation coefficients, ranging from 0 to 1, where a higher value indicates higher agreement between the compared modalities (Fig. S4). Similar evaluations were also performed for WML metrics (Fig. S6)

561 Since typically FLAIR and T2-weighted images are considered more sensitive to WML 562 and PVS, respectively,^{8,9} due to a higher contrast between the cerebral parenchyma and the WML/PVS, we also evaluated the suitability of assessing WML and PVS with only the 563 564 T1-weighted images in two ways: 1) we measured the correlation between the number of 565 WML/PVS voxels measured on T1-weighted versus FLAIR/T2-weighted images, to 566 determine the strength and direction of their relationship (Fig. S5); 2) to confirm the spatial 567 agreement of the WML/PVS voxels across the two modalities, we measured the overlap 568 of the WML/PVS voxels identified on T1-weighted images with the WML/PVS voxels (and 569 the adjacent 3 voxels to account for any residual misalignment between modalities) 570 identified from FLAIR/T2-weighted images rigidly registered to the corresponding T1-571 weighted images.

572

573 Statistical analysis

574 All the models and simulations described below were adjusted for intracranial volume and 575 the following baseline factors (as reported on the documented clinical assessment and 576 subject health history): age, sex, educational level, race, body mass index, CDR global 577 score, family history of dementia (positive if any of the participants' parents were reported 578 to have dementia), and history of hypertension, dyslipidemia, diabetes, and cardio-579 /cerebro-vascular disease (i.e., any of the following: heart failure, angina, cardiac arrest, 580 stent placement, coronary artery bypass, pacemaker, defibrillator, heart valve 581 replacement or repair, stroke, transient ischemic attack). These factors were all available

for more than 97% participants. We used missing indicators for handling missing valuesin the covariates.

The associations of our PVS markers with cognitive status (non-dementia versus 584 585 dementia) and the other covariates at the baseline visit were assessed with general linear 586 models stratified according to study. The association of our PVS markers at the baseline 587 with subsequent risk of developing dementia was assessed in each study independently 588 with Cox proportional-hazards models and the results were integrated using a random-589 effects meta-analysis to account for potential differences among the studies (two-stage 590 pooled analysis). Inter-study heterogeneity was assessed statistically with the I². Person-591 time was calculated from the baseline clinical visit until the visit where the dementia was 592 documented or the last clinical visit, whichever occurred first. The proportional-hazard 593 assumptions were verified by assessing the relationship between Schoenfeld residuals 594 and time.⁶⁴ Additionally, we analyzed these associations by combining in the same model 595 all the individual-level data (simple pooled analysis), stratified according to study and 596 adjusted for the same covariates, and used penalized splines to assess their deviation 597 from linearity.⁶⁵ In addition to the covariates used in all the other models, the linear models 598 and Cox-regression models above were also controlled for the time interval between the 599 MRI scan and the clinical visit of the cognitive assessment at the baseline.

Linear mixed-effects models with random intercepts and slopes for each participant were used to estimate the longitudinal trajectories of grey matter volume, cortical thickness, and white matter volume according to baseline PVS count or mean diameter. In addition to the covariates used in all the other models, the linear mixed-effects models were also adjusted for the value of the dependent variable at the baseline, and the following

605 characteristics of the MRI scanner that may influence the longitudinal estimation of brain 606 atrophy: field strength, manufacturer, and intra-individual consistency of the protocol used 607 for the longitudinal MRI acquisitions (consistent versus non-consistent protocol). Interaction terms between time and all predictors were included as well to estimate the 608 marginal per-year effects of each predictor. Linear mixed-effects models with random 609 610 intercepts and slopes for each participant were also used to estimate and compare the 611 longitudinal trajectories of PVS and WML markers in non-demented individuals who 612 converted to dementia versus non-converters.

613 Sensitivity analyses for all the models above included: 1) the individual assessment of 614 other potential confounding factors available only in a subsample of the participants 615 (92.6% history of tobacco smoking, 90.0% Apolipoprotein E alleles, 39.0% amyloid- β and 616 24.7% tau status as assessed on cerebrospinal fluid and/or Positron-Emission 617 Tomography); 2) the use of MMSE rather than CDR for the cognitive evaluation (available 618 in 70.3% of the participants); 3) the assessment of MRI acquisition artifacts or factors that 619 could have influenced the estimation of the vascular markers. In sensitivity 620 analyses, hazard ratios were estimated from Cox models with stratification according to 621 study cohort (simple pooled analysis) owing to smaller sample sizes in the individual 622 studies.

To evaluate the potential utility of PVS markers as a screening tool in clinical trials, we computed the sample size needed to detect improvements in cognitive decline trajectories when restricting the sample based on the baseline values of the marker, and compared it to the sample size requested without any restriction. The clinical trials were simulated with 1:1 allocation of active treatment and placebo, assuming a 30% treatment effect on cognition over time, a trial duration of 48 months, and cognitive testing every 12
months. 500 simulations were generated with bootstrap iteration.

- 630 All the analyses were based on *a priori* hypotheses, but to account for two variables of
- 631 interest (PVS count and mean diameter), we present P values that were corrected for
- 632 multiple comparisons with the use of the Holm–Bonferroni procedure.⁶⁶ In brain regional
- analyses, the correction for multiple comparisons was performed across all the
- analyzed regions. All statistical analyses were performed in R v4.3.3. The following R
- 635 packages were used for the statistical analyses and generation of the plots: *survival*
- 636 was used for fitting the Cox proportional-hazards models;⁶⁷ meta was used for the meta-

637 analysis;⁶⁸ *Imer4* was used for fitting the non-linear mixed models;⁶⁹ ggeffects was used

638 for estimating the marginal effects in the non-linear mixed models;⁷⁰ longpower was

- 639 used for the simulation of clinical trials;⁷¹ ggseg was used for generating the plots with
- 640 the brain statistics;⁷² ggplot2 was used for generating all the other plots.⁷³

641 Acknowledgements

642 The authors thank all the participants and personnel involved in the data collection.

643 The authors G.B. and M.H. are supported by a grant (U54CA261717 to Dr. Hayden-

644 Gephart) from the National Institutes of Health (NIH), J.C. is supported by grants

645 RF1MH123223, R01AG070825, and R01NS128486 from the NIH.

- 646 The authors thank Dr. Michael Greicius, M.D., from the Department of Neurology at 647 Stanford University for valuable discussion of the manuscript.
- 648 The image computing resources provided by the Laboratory of Neuro Imaging Resource

649 (LONIR) at the University of Southern California are supported in part by NIH National

650 Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41EB015922.

Data used in preparation of this article include data obtained from the MarkVCID consortium. A complete listing of MarkVCID investigators can be found at:

653 <u>www.markvcid.org</u>.

654 **Disclosures**: G.B. is inventor on a patent application related to this work filed by

655 Stanford University. The other authors declare that they have no competing interests.

ADNI: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;

662 BioClinica, Inc.: Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.: Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La 663 664 Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & 665 666 Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & 667 Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; 668 Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda 669 Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of 670 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health 671 672 (www.fnih.org). The grantee organization is the Northern California Institute for Research 673 and Education, and the study is coordinated by the Alzheimer's Therapeutic Research 674 Institute at the University of Southern California. ADNI data are disseminated by the 675 Laboratory for Neuro Imaging at the University of Southern California.

676 **NACC**: The National Alzheimer's Coordinating Center (NACC) database is funded by 677 NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: 678 P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 679 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 680 681 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 682 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 683 684 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI

685 David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald 686 687 Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda 688 Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI 689 690 Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI 691 Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 692 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 693 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 694 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 695 696 AG072959 (PI James Leverenz, MD).

OASIS: Data were provided in part by the Open Access Series of Imaging Studies
(OASIS) OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T.
Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781,
P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352, NIH
P30 AG066444, AW00006993.

- AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary ofEli Lilly.
- AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiaryof Eli Lilly.

706 **MarkVCID**: MarkVCID was launched in 2016 by the NIH's National Institute of

707 Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA), and

708	consists of research groups across the United States. The primary goal of MarkVCID is
709	to generate a suite of validated biomarkers ready for application to clinical trials aimed
710	at identifying disease-modifying therapies for VCID. For up-to-date information, see
711	www.markvcid.org. Data collection and sharing was funded by NINDS/NIA as part of the
712	Biomarkers Consortium for Vascular Contributions to Cognitive Impairment and
713	Dementia (MarkVCID): U24NS100591, UH2NS100599, UH2NS100605,
714	UH2NS100588, UH2NS100608, UH2NS100606, UH2NS100598, UH2NS100614.
715	Human Connectome Project: Data were provided in part by the Human Connectome
716	Project (HCP), WU-Minn Consortium (1U54MH091657) funded by the 16 NIH Institutes
717	and Centers that support the NIH Blueprint for Neuroscience Research; and by the
718	McDonnell Center for Systems Neuroscience at Washington University. Data from
719	HCP-Aging cohort was supported by the National Institute on Aging of the
720	National Institutes of Health under Award Number U01AG052564. Data from HCP-
721	Development cohort was supported by the National Institute of Mental Health of
722	the National Institutes of Health under Award Number U01MH109589. The content is
723	solely the responsibility of the authors and does not necessarily represent the official
724	views of the National Institutes of Health. MRI and clinical data can be accessed from
725	https://www.humanconnectome.org.

727 Author contributions

728	Giuseppe Barisano, Jeiran Choupan and Melanie Hayden-Gephart designed the study.
729	Giuseppe Barisano developed the method for robust perivascular space segmentation.
730	Giuseppe Barisano processed the MRI data, gathered the demographic and clinical
731	data, and performed the statistical analysis. Giuseppe Barisano, Jeiran Choupan and
732	Melanie Hayden-Gephart vouch for the data and the analysis. Giuseppe Barisano
733	developed the interactive website. Giuseppe Barisano wrote the first draft of the
734	manuscript. All the authors contributed to result interpretation and manuscript editing.
735	All the authors agreed to publish the paper.
736	
737	Data used in preparation of this article were obtained from the Alzheimer's Disease
738	Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators
739	within the ADNI contributed to the design and implementation of ADNI and/or provided
740	data but did not participate in analysis or writing of this report.

742 Figures & Tables

Characteristic	Overall	ADNI (N=2621)	NACC	OASIS	
	(N=10,004)		(N=6029)	(N=1354)	
Age at baseline – yr	71.1 ± 9.7	72.9 ± 7.5	70.6 ± 10.5	70.2 ± 9.2	
Female – %	56.6	48.4	60.7	54.8	
Education – yr	15.7 ± 3.1	16.1 ± 2.7	15.5 ± 3.2	15.8 ± 2.7	
Race – %					
White	84.7	87.8	83.6	83.5	
Black	11.6	7.7	12.5	15.1	
Asian	0.8	0.2	1.2	0	
American Indians	1.8	2.3	1.8	0.6	
More than one reported	0.4	1.3	0	0.2	
Body Mass Index – kg/m ²	27.2 ± 5.2	27.1 ± 5.1	27.1 ± 5.2	27.8 ± 5.4	
Dyslipidemia – %	52.7	52.9	53.8	47.6	
Hypertension – %	47.5	47.6	47.5	47.1	
Diabetes – %	12.3	10.3	13.5	10.6	
History of cardio- /cerebro-vascular disease – %	28	34.1	26	25.1	

Family history of dementia – %	51.2	52.5	49.8	55.1	
History of tobacco smoking* – %	37.7	24.4	42.5	44.9	
APOE* – %					
ε2ε2	0.3	0.3	0.3	0.6	
ε2ε3	9.2	7.4	9.7	10.6	
ε2ε4	2.4	2.1	2.4	3.3	
ε3ε3	49	46.8	50.6	47.3	
ε3ε4	31.8	34.1	30.5	32.4	
٤4٤4	7.2	9.4	6.5	5.8	
A-beta positivity* – %	50.1	62.7	40.6	32.7	
Tau positivity* – %	64.7	53.1	45.0	59.2	
WM-PVS count	428.0	384.0	447.0	427.0	
	(339 to 530)	(306 to 483)	(358 to 551)	(344 to 520)	
BG-PVS count	133.0	107.0	143.0	132.0	
	(106 to 166)	(88 to 143)	(117 to 174)	(113 to 156)	
WM-PVS mean	2.0	2.0	1.9	2.0	
diameter – mm	(1.87 to 2.07)	(1.94 to 2.17)	(1.86 to 2.03)	(1.88 to 2.05)	
BG-PVS mean	1.6	1.6	1.5	1.6	
diameter – mm	(1.51 to 1.64)	(1.55 to 1.71)	(1.51 to 1.60)	(1.53 to 1.62)	

P-WML volume –	330.0	596.5	230.0	257.5
mm ³	(0 to 1613)	(46 to 1989.50)	(0 to 1406)	(0 to 1674.25)
D-WML volume –	16.0	34.0	8.0	24.0
mm ³	(1 to 72)	(7 to 104)	(0 to 53)	(4 to 89.75)

743

744 **Table 1. Baseline characteristics of the study population.**

745 Plus–minus values are means ± standard deviations, entries with parentheses are

746 medians (interquartile range). Data on education were missing for 0.15% of the

participants, on race for 0.8%, on body mass index for 2.6%, on dyslipidemia for 1.2%,

on hypertension and diabetes for 0.7%, on history of cardio-/cerebro-vascular disease

on 0.5%, on family history for dementia for 2.7%. Data from three studies — the

750 Alzheimer's Disease Neuroimaging Initiative (ADNI), the National Alzheimer's

751 Coordinating Center (NACC), and the Open Access Series of Imaging Studies (OASIS)

752 — are shown. Race was reported by the participant. *Total number of subjects with

available history of tobacco smoking, Apolipoprotein E (APOE) genotype, amyloid-beta

status and tau status were 9267, 8599, 3906, and 2466, respectively.



757 Figure 1. Forest plots and spline plots for the Associations of PVS and WML

758 markers with Dementia Risk.

759	In two-stage pooled analyses that combined individual-participant data from three
760	studies (Panels A-F), each additional 100 WM-PVS (Panel A) and 10 BG-PVS (Panel B)
761	were associated with 20% and 9% decrease in dementia risk, each additional 0.1 mm
762	increase in mean WM-PVS (Panel C) and BG-PVS (Panel D) diameter were associated
763	with 9% and 20% increase in dementia risk, and each unit increase of the log-
764	transformed P-WML volume (Panel E) was associated with 13% increase in dementia
765	risk. Log-transformed D-WML volume (Panel F) was not associated with dementia risk.
766	In each graph, the size of the squares indicates the weight given to the study, and the
767	width of the diamond indicates the 95% confidence interval for the overall association
768	estimate. Between-study heterogeneity was statistically assessed with the use of I ² .
769	The spline analysis of pooled data (Panels G-L) supported a linear association over the
770	range of WM-PVS count (Panel G; 2.5 th -97.5 th percentile, 206 to 762), BG-PVS count
771	(Panel H; 2.5 th -97.5 th percentile, 71 to 244), WM-PVS diameter (Panel I; 2.5 th -97.5 th
772	percentile, 1.77 to 2.30 mm), BG-PVS diameter (Panel J; 2.5 th -97.5 th percentile, 1.44 to
773	1.79) and P-WMH volume (Panel K; 2.5 th -97.5 th percentile, 0 to 9.1) within the overall
774	population. Shaded areas indicate 95% confidence intervals, and the red line at 1.0
775	indicates the reference. Box plots at the bottom of the graphs show the distributions of
776	the marker. The vertical bar indicates the median, and the ends of the box the
777	interquartile range; the whiskers extend to values no farther than 1.5 times the
778	interquartile range (which may be past the graphed area).

- 780 Data from three studies the Alzheimer's Disease Neuroimaging Initiative (ADNI), the
- 781 Open Access Series of Imaging Studies (OASIS), and the National Alzheimer's
- 782 Coordinating Center (NACC) are shown. Hazard ratios were estimated from Cox
- 783 models stratified according to study cohort with adjustment for age, sex, race,
- educational level, body mass index, CDR global score at the baseline, history of
- diabetes, cardio-/cerebro-vascular disease, hypertension, dyslipidemia, family history of
- dementia, intracranial volume and the time interval between the MRI scan and the
- 787 clinical visit of the cognitive assessment at the baseline.



Figure 2. Plots for the estimated trajectories of brain atrophy in relation to PVS
and WML markers.

- Top rows in each panel depict the effect of baseline PVS and WML markers on the
- 793 trajectories of grey matter volume, cortical thickness, and white matter volume (Panels
- A-C, respectively). For each marker, equally spaced values from the low-risk (red),
- 795 medium-risk (blue), and high-risk (yellow) tertile are shown (tertile limits in Table S16).
- 796 Shaded areas indicate 95% confidence intervals. The regional analysis (bottom rows in

797 each panel) across cortical parcellations according to the Desikan-Killiany atlas reports 798 the estimated volume or thickness preserved (positive values in red) or lost (negative 799 values in blue) per year for each additional unit increase in the vascular marker. Only 800 estimated values for regions that remained statistically significant after correction for 801 multiple comparisons (68 comparisons) are shown; non-significant regions are greved 802 out. See also Tables S11-13 for grey matter volume, cortical thickness, and white 803 matter volume, respectively. Estimates and corrected significance (P values) obtained 804 from fully adjusted linear mixed-effects models with random intercepts and slopes for 805 each individual participant (N=3389 and 14,229 timepoints MRI scans). All models were 806 adjusted for age, sex, race, educational level, body mass index, CDR global score at 807 the baseline, history of diabetes, cardio-/cerebro-vascular disease, hypertension, 808 dyslipidemia, family history of dementia, intracranial volume, the baseline value of the 809 dependent variable (grey matter volume, cortical thickness, or white matter volume), 810 field strength, manufacturer, and intra-individual consistency of the protocol used for the 811 longitudinal MRI acquisitions (consistent versus non-consistent protocol).



813

Figure 3. Plots for the estimated longitudinal trajectories of PVS or WML markers according to conversion to dementia status.

816 Estimated longitudinal trajectories of WM-PVS (A-B), BG-PVS (C-D), and WML (E)

817 markers for non-demented individuals who converted to dementia (converters, red) and

- 818 those that did not convert to dementia (non-converters, cyan). Trajectories are
- 819 estimated from fully adjusted linear mixed-effect models; the adjusted p-values (P)
- 820 indicate whether the trajectories are significantly different between the groups after
- 821 correction for multiple comparisons. Shaded areas indicate 95% confidence intervals.

822 For WM-PVS markers (panels A-B), we estimated in each lobe of the left (L) and right 823 (R) hemispheres the group-effect (expressed as T-value) for the longitudinal trajectories 824 of the corresponding marker: positive values in red indicate significantly higher (i.e., less 825 negative) slopes for non-converters versus converters, whereas negative values in blue 826 indicate significantly lower (i.e., more negative) slopes for non-converters versus 827 converters. Lobes where the longitudinal trajectories were not significantly different 828 between converters and non-converters after correction for multiple comparisons are 829 greyed-out. Estimates and corrected significance obtained from fully adjusted linear 830 mixed-effects models with random intercepts and slopes for each individual participant 831 (N=3389 and 14,229 timepoints MRI scans).



Figure 4. Barplots for the relative sample size in simulated clinical trials enriched
using PVS or WML markers.

836 Relative sample sizes for simulated clinical trials in non-demented individuals pooled 837 from three studies (the Alzheimer's Disease Neuroimaging Initiative, the Open Access 838 Series of Imaging Studies, and the National Alzheimer's Coordinating Center). The 839 simulations had statistical power of 80% at α = .05 and assumed a 30% treatment effect 840 for slopes in cognitive decline, 1:1 allocation of treatment, total trial length of 48 months, 841 and outcome measures every 12 months. All available longitudinal cognitive data (40,307 cognitive assessments from 7518 non-demented subjects) were used in these 842 843 fully-adjusted models. All estimates and standard errors are across 500 bootstrap 844 iterations. The reference model (without enrichment and with 100% inclusion) included 845 all the tertiles. In the two enrichment models for each marker ("medium-risk+high-risk

- 846 tertiles", red bars; "high-risk only tertile", blue bars), only participants in the indicated
- tertiles were included. Tertile limits for each marker are reported in Table S16.

848

849

850

852 References

853	1.	Debette, S., Schilling, S., Duperron, M. G., Larsson, S. C. & Markus, H. S. Clinical
854		Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A
855		Systematic Review and Meta-analysis. JAMA Neurol. 76, 81–94 (2018).
856	2.	Wardlaw, J. M., Smith, C. & Dichgans, M. Small vessel disease: mechanisms and
857		clinical implications. Lancet Neurol. 18, 684–696 (2019).
858	3.	Arvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A. & Schneider, J.
859		A. Relation of cerebral vessel disease to Alzheimer's disease dementia and
860		cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 15,
861		934–943 (2016).
862	4.	Roher, A. E. et al. Intracranial atherosclerosis as a contributing factor to
863		Alzheimer's disease dementia. Alzheimers. Dement. 7, 436 (2011).
864	5.	Dolan, H. et al. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore
865		Longitudinal Study of Aging cohort. Ann. Neurol. 68, 231–240 (2010).
866	6.	Fu, C. et al. Comorbidity in dementia: an autopsy study. Arch. Pathol. Lab. Med.
867		128 , 32–38 (2004).
868	7.	Beach, T. G. et al. Circle of Willis atherosclerosis: association with Alzheimer's
869		disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 113, 13–
870		21 (2007).
871	8.	Duering, M. et al. Neuroimaging standards for research into small vessel
872		disease—advances since 2013. <i>Lancet Neurol.</i> 22 , 602–618 (2023).

- 873 9. Barisano, G. *et al.* Imaging perivascular space structure and function using brain
 874 MRI. *Neuroimage* 257, 119329 (2022).
- 10. Schwartz, D. L. *et al.* Autoidentification of perivascular spaces in white matter
- using clinical field strength T1 and FLAIR MR imaging. *Neuroimage* **202**, (2019).
- 11. Rashid, T. *et al.* Deep Learning Based Detection of Enlarged Perivascular Spaces
- on Brain MRI. *Neuroimage. Reports* **3**, (2023).
- 12. Sepehrband, F. *et al.* Image processing approaches to enhance perivascular
- space visibility and quantification using MRI. *Sci. Rep.* **9**, 12351 (2019).
- 13. Ballerini, L. *et al.* Perivascular Spaces Segmentation in Brain MRI Using Optimal
 3D Filtering. *Sci. Rep.* 8, 1–11 (2018).
- 14. Ramirez, J. et al. Imaging the Perivascular Space as a Potential Biomarker of
- Neurovascular and Neurodegenerative Diseases. *Cell. Mol. Neurobiol.* 36, 289–
 299 (2016).
- 15. Boespflug, E. L. et al. MR Imaging–based Multimodal Autoidentification of
- 887 Perivascular Spaces (mMAPS): Automated Morphologic Segmentation of
- 888 Enlarged Perivascular Spaces at Clinical Field Strength. *Radiology* 286, 632–642
 889 (2018).
- 16. Frangi, A. F., Niessen, W. J., Vincken, K. L. & Viergever, M. A. Multiscale vessel
- 891 enhancement filtering. in *Medical Image Computing and Computer-Assisted*
- 892 Intervention— Miccai'98. 1496, 1496, 130–137 (Springer, Berlin, Heidelberg,
- 893 1998).
- 17. Sepehrband, F. *et al.* Volumetric distribution of perivascular space in relation to

- mild cognitive impairment. *Neurobiol. Aging* **99**, 28–43 (2021).
- 18. Caprihan, A. *et al.* A trichotomy method for defining homogeneous subgroups in a
- 897 dementia population. *Ann. Clin. Transl. Neurol.* **10**, 1802–1815 (2023).
- 19. Vernooij, M. W. *et al.* Dementia imaging in clinical practice: a European-wide
- survey of 193 centres and conclusions by the ESNR working group.
- 900 *Neuroradiology* **61**, 633–642 (2019).
- 901 20. Insel, P. S. *et al.* Determining clinically meaningful decline in preclinical Alzheimer
 902 disease. *Neurology* 93, E322–E333 (2019).
- 903 21. Barisano, G., Sheikh-Bahaei, N., Law, M., Toga, A. W. & Sepehrband, F. Body
- mass index, time of day and genetics affect perivascular spaces in the white
 matter. *J. Cereb. Blood Flow Metab.* **41**, 1563–1578 (2021).
- 906 22. Lynch, K. M., Sepehrband, F., Toga, A. W. & Choupan, J. Brain perivascular
- 907 space imaging across the human lifespan. *Neuroimage* **271**, 120009 (2023).
- 23. Kim, H. G. *et al.* MRI-visible Dilated Perivascular Space in the Brain by Age: The
 Human Connectome Project. *Radiology* **306**, (2023).
- 910 24. Puonti, O., Iglesias, J. E. & Van Leemput, K. Fast and sequence-adaptive whole-
- 911 brain segmentation using parametric Bayesian modeling. *Neuroimage* 143, 235–
 912 249 (2016).
- 913 25. Mestre, H. *et al.* Flow of cerebrospinal fluid is driven by arterial pulsations and is
 914 reduced in hypertension. *Nat. Commun.* 9, 4878 (2018).
- 915 26. Holstein-Rønsbo, S. *et al.* Glymphatic influx and clearance are accelerated by
- 916 neurovascular coupling. *Nat. Neurosci.* **26**, 1042–1053 (2023).

917	27.	lliff.	. J. J	. et	al.	А	paravascular	pathwa	/ facilitates	CSF	flow	through	the	brain
~ - /														

- 918 parenchyma and the clearance of interstitial solutes, including amyloid β. Sci.
- 919 *Transl. Med.* **4**, 1–11 (2012).
- 920 28. Iliff, J. J. et al. Cerebral Arterial Pulsation Drives Paravascular CSF-Interstitial
- 921 Fluid Exchange in the Murine Brain. *J. Neurosci.* **33**, 18190–18199 (2013).
- 922 29. Kress, B. T. *et al.* Impairment of paravascular clearance pathways in the aging
 923 brain. *Ann. Neurol.* **76**, 845–861 (2014).
- 30. Hays, C. C., Zlatar, Z. Z. & Wierenga, C. E. The Utility of Cerebral Blood Flow as
- 925 a Biomarker of Preclinical Alzheimer's Disease. *Cell. Mol. Neurobiol.* 36, 167–179
 926 (2016).
- 927 31. Duan, W. *et al.* Cerebral Blood Flow Is Associated with Diagnostic Class and
 928 Cognitive Decline in Alzheimer's Disease. *J. Alzheimer's Dis.* **76**, 1103–1120
 929 (2020).
- 32. Claassen, J. A. H. R., Thijssen, D. H. J., Panerai, R. B. & Faraci, F. M. Regulation
 of cerebral blood flow in humans: physiology and clinical implications of
 autoregulation. *Physiol. Rev.* **101**, 1487–1559 (2021).
- 933 33. Schaeffer, S. & ladecola, C. Revisiting the neurovascular unit. *Nat. Neurosci.* 24,
 934 1198–1209 (2021).
- 34. Smeijer, D., Ikram, M. K. & Hilal, S. Enlarged Perivascular Spaces and Dementia:
 A Systematic Review. *J. Alzheimers. Dis.* 72, 247–256 (2019).
- 937 35. Rensma, S. P., van Sloten, T. T., Launer, L. J. & Stehouwer, C. D. A. Cerebral
- 938 small vessel disease and risk of incident stroke, dementia and depression, and

- 939 all-cause mortality: A systematic review and meta-analysis. *Neurosci. Biobehav.*
- 940 *Rev.* **90**, 164–173 (2018).
- 941 36. Zhu, Y.-C. et al. High Degree of Dilated Virchow-Robin Spaces on MRI is
- 942 Associated with Increased Risk of Dementia. J. Alzheimer's Dis. 22, 663–672
- 943 (2010).
- 37. Romero, J. R. *et al.* MRI-Visible Perivascular Spaces and Risk of Incident
 Dementia. *Neurology* 99, e2561–e2571 (2022).
- 946 38. Xiong, L. et al. Dementia incidence and predictors in cerebral amyloid angiopathy
- 947 patients without intracerebral hemorrhage. *J. Cereb. Blood Flow Metab.* 38, 241–
 948 249 (2018).
- 949 39. Ding, J. et al. Large Perivascular Spaces Visible on Magnetic Resonance
- 950 Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia.
- 951 JAMA Neurol. **74**, 1105 (2017).
- 952 40. Bouvy, W. H. et al. Visualization of Perivascular Spaces and Perforating Arteries
- 953 With 7 T Magnetic Resonance Imaging. *Invest. Radiol.* **49**, 307–313 (2014).
- 41. Jochems, A. C. C. *et al.* Relationship Between Venules and Perivascular Spaces
 in Sporadic Small Vessel Diseases. *Stroke* **51**, 1503–1506 (2020).
- 956 42. George, I. C. *et al.* A Novel Method to Measure Venular Perivascular Spaces in
- 957 Patients with MS on 7T MRI. *Am. J. Neuroradiol.* **42**, 1069–1072 (2021).
- 958 43. Weiner, M. W. et al. The Alzheimer's Disease Neuroimaging Initiative 3:
- 959 Continued innovation for clinical trial improvement. Alzheimer's and Dementia **13**,
- 960 561–571 (Elsevier Inc., 2017).

961	44.	Beekly, D. L. et al. The National Alzheimer's Coordinating Center (NACC)
962		database: The uniform data set. Alzheimer Dis. Assoc. Disord. 21, 249–258
963		(2007).
964	45.	LaMontagne, P. J. et al. OASIS-3: Longitudinal Neuroimaging, Clinical, and
965		Cognitive Dataset for Normal Aging and Alzheimer Disease. medRxiv
966		2019.12.13.19014902 (2019). doi:10.1101/2019.12.13.19014902
967	46.	Petersen, R. C. et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical
968		characterization. Neurology 74, 201 (2010).
969	47.	Hachinski, V. C. et al. Cerebral Blood Flow in Dementia. Arch. Neurol. 32, 632–

970 637 (1975).

971 48. Yesavage, J. A. *et al.* Development and validation of a geriatric depression

972 screening scale: a preliminary report. *J. Psychiatr. Res.* **17**, 37–49 (1982).

- 973 49. Budelier, M. M. & Bateman, R. J. Biomarkers of Alzheimer Disease. *J. Appl. Lab.*974 *Med.* 5, 194 (2020).
- 50. Landau, S. M. *et al.* Amyloid deposition, hypometabolism, and longitudinal
 cognitive decline. *Ann. Neurol.* **72**, 578–586 (2012).
- 977 51. Royse, S. K. *et al.* Validation of amyloid PET positivity thresholds in centiloids: a

978 multisite PET study approach. *Alzheimer's Res. Ther.* **13**, 1–10 (2021).

- 979 52. Jagust, W. J. *et al.* The ADNI PET Core. *Alzheimers. Dement.* **6**, 221 (2010).
- 980 53. Fagan, A. M. et al. Comparison of analytical platforms for cerebrospinal fluid
- 981 measures of A β 1-42, total tau and p-tau181 for identifying Alzheimer's disease
- amyloid plaque pathology. *Arch. Neurol.* **68**, 1137 (2011).

983	54.	Shaw, L. M. et al. Cerebrospinal Fluid Biomarker Signature in Alzheimer's
984		Disease Neuroimaging Initiative Subjects. Ann. Neurol. 65, 403 (2009).
985	55.	Morris, J. C. The Clinical Dementia Rating (CDR). Neurology 43, 2412.2-2412-a
986		(1993).
987	56.	Folstein, M. F., Folstein, S. E. & McHugh, P. R. 'Mini-mental state'. A practical
988		method for grading the cognitive state of patients for the clinician. J. Psychiatr.
989		<i>Res.</i> 12 , 189–198 (1975).
990	57.	Fischl, B. FreeSurfer. Neuroimage 62, 774–781 (2012).
991	58.	Reuter, M., Schmansky, N. J., Rosas, H. D. & Fischl, B. Within-Subject Template
992		Estimation for Unbiased Longitudinal Image Analysis. Neuroimage 61, 1402–1418
993		(2012).
994	59.	Barisano, G. et al. The effect of prolonged spaceflight on cerebrospinal fluid and
995		perivascular spaces of astronauts and cosmonauts. Proc. Natl. Acad. Sci. 119,
996		e2120439119 (2022).
997	60.	Wilcock, D. et al. MarkVCID cerebral small vessel consortium: I. Enrollment,
998		clinical, fluid protocols. Alzheimers. Dement. 17, 704–715 (2021).
999	61.	Somerville, L. H. et al. The Lifespan Human Connectome Project in Development:
1000		A large-scale study of brain connectivity development in 5–21 year olds.
1001		<i>Neuroimage</i> 183 , 456–468 (2018).
1002	62.	Bookheimer, S. Y. et al. The Lifespan Human Connectome Project in Aging: An
1003		overview. Neuroimage 185, 335–348 (2019).
1004	63.	Van Essen, D. C. et al. The WU-Minn Human Connectome Project: An overview.

- 1005 *Neuroimage* **80**, 62–79 (2013).
- 1006 64. Schoenfeld, D. Partial residuals for the proportional hazards regression model.
 1007 *Biometrika* 69, 239–241 (1982).
- 1008 65. Durrleman, S. & Simon, R. Flexible regression models with cubic splines. Stat.
- 1009 *Med.* **8**, 551–561 (1989).
- 1010 66. Holm, S. A Simple Sequentially Rejective Multiple Test Procedure. *Scand. J. Stat.*1011 6, 65–70 (1979).
- 1012 67. Therneau, T. M. & Grambsch, P. M. *Modeling Survival Data: Extending the Cox*
- 1013 *Model*. (Springer New York, 2000). doi:10.1007/978-1-4757-3294-8
- 1014 68. Schwarzer, G., Carpenter, J. R. & Rücker, G. Meta-Analysis with R. (Springer
- 1015 International Publishing, 2015). doi:10.1007/978-3-319-21416-0
- 1016 69. Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting Linear Mixed-Effects
- 1017 Models Using Ime4. J. Stat. Softw. 67, 1–48 (2015).
- 1018 70. Lüdecke, D. ggeffects: Tidy Data Frames of Marginal Effects from Regression
 1019 Models. *J. Open Source Softw.* **3**, 772 (2018).
- 1020 71. Iddi, S. & C Donohue, M. Power and Sample Size for Longitudinal Models in R --
- 1021 The longpower Package and Shiny App. *R J.* **14**, 264–282 (2022).
- 1022 72. Mowinckel, A. M. & Vidal-Piñeiro, D. Visualization of Brain Statistics With R
- 1023 Packages ggseg and ggseg3d. Adv. Methods Pract. Psychol. Sci.
- 1024 251524592092800 (2020). doi:10.1177/2515245920928009
- 1025 73. Wickham, H. ggplot2. (Springer International Publishing, 2016). doi:10.1007/978-

 1026
 3-319-24277-4

1027